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A conference was convened by the Korean Diabetes Association and the Korean Endocrine Society on September 7, 2009 to dis-
cuss and organize the results of research on intensive glucose control for the prevention of cardiovascular disease in patients with 
type 2 diabetes. Professor Kyung Soo Park led the conference, and Professors Kwang Won Kim and Ho Young Son acted as chair-
men. Professors Doo Man Kim, Tae Sun Park, and Bong Soo Cha reported on intensive glucose control and diabetic complica-
tions, including the UK Prospective Diabetes Study (UKPDS), Diabetes Control and Complication Trial (DCCT) research results, 
the recently published Action to Control Cardiovascular Risk in Diabetes (ACCORD), Action in Diabetes and Vascular Disease: 
Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE), and Veterans Affairs Diabetes Trial (VADT) re-
search, as well as meta-analyses. Professor Jeong-Taek Woo reported on the manuscript written by the committee for the Korean 
Diabetes Association which dealt with the treatment of diabetes mellitus. Professors Kyung Soo Ko, Joong Yeol Park, Hyun Shik 
Son, Moon-Kyu Lee, Dong-Won Byun, and Yoon-Sok Chung participated in the discussion and collected information for the man-
uscript from all of the participants. The aim of the debate was to determine how to establish target goals for intensive glucose con-
trol and how to individualize those goals. The participants concluded that there was no need to modify the recommendation of 
maintaining an HbA1c under 6.5%, the current blood glucose treatment goal that is recommended by the Korean Diabetes As-
sociation. In addition, individual target goals for glucose control were recommended depending on the situation of each patient. 
We report on the consensus statement from the meeting.
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*A review of recent research by the Korean Diabetes Association and the 
Korean Endocrine Society regarding intensive glucose control and the 
prevention of cardiovascular diseases.
INTRODUCTION
The pathogenesis of type 2 diabetes is characterized by in-
creased insulin resistance and decreased insulin secretion. An 
increase in insulin secretion occurs in an attempt to maintain 
proper glucose metabolism by overcoming the insulin resis-
tance in people with normal glucose tolerance. Type 2 diabetes 
occurs as a result of progressive pancreatic β-cell dysfunction 
that disturbs normal glucose metabolism.
  In addition to elevated blood glucose levels, patients with 
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type 2 diabetes frequently suffer from several additional con-
ditions such as obesity and other features of metabolic syn-
drome. Therefore, the risk of macrovascular as well as micro-
vascular complications should be added to the cardiovascular 
risk factors that are associated with high blood glucose level. 
Results from the UK Prospective Diabetes Study (UKPDS) [1] 
showed that newly diagnosed patients with type 2 diabetes 
who received intensive glucose control for ten years (HbA1c 
mean value, 7%) had a 25% decreased risk of microvascular 
complications compared to patients who received convention-
al treatment (7.9%). Because HbA1c and the risk of microvas-
cular complications have a linear relationship, the American 
Diabetes Association [2] set the goal of glycemic control to be 
below an HbA1c of 7%. The Korean Diabetes Association [3] 
set the target HbA1c below 6.5% based on the Kumamoto re-
search [4] results in Japan. However, the beneficial effects of 
intensive glycemic control on great vessel disease, especially 
cardiovascular disease, are unclear. According to the UKPDS, 
intensive glycemic treatment showed only a slight benefit for 
the prevention of cardiovascular disease (16% decrease; P = 
0.052).
  About ten years ago, following the UKPDS report, addi-
tional studies were planned to determine whether intensive 
glucose control in patients with type 2 diabetes (who had a 
relatively high risk of cardiovascular disease) reduced the oc-
currence of cardiovascular disease. The results of these studies 
were recently published [5-8] and showed contradictory re-
sults. In one study, mortality was increased in the intensive 
glucose control group [5]. The Korean Diabetes Association 
and the Korean Endocrine Society thought that the medical 
literature on this topic would be confusing to readers. There-
fore, a meeting was organized to discuss the literature and to 
provide a consensus statement regarding the studies and their 
results.
SUMMARY OF THE RECENT RESEARCH 
RESULTS
Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) study [5]
The purpose of this study was to determine whether cardio-
vascular disease was prevented when blood glucose was main-
tained at normal levels in patients with type 2 diabetes who 
also suffered from cardiovascular disease or had risk factors 
for cardiovascular disease. 10,251 patients with a mean age of 
62.2 years (baseline HbA1c median value, 8.3%) were followed 
for four to eight years (average 5.6 years). These patients re-
ceived either comprehensive intensive therapy with an HbA1c 
target of less than 6.0% or standard therapy with a target 
HbA1c of 7.0% to 7.9%. However, a higher mortality rate in 
the intensive therapy group led to the discontinuation of the 
research after a mean follow-up period of 3.5 years. After one 
year, stable median HbA1c levels of 6.4% and 7.5% were 
achieved in the intensive-therapy group and the standard-
therapy group, respectively. There were no statistical differenc-
es in the primary outcomes between the two groups. However, 
257 patients in the intensive treatment group and 203 in the 
standard treatment group died during the study (hazard ratio, 
1.22; 95% confidence interval [CI], 1.01 to 1.46; P = 0.04), re-
sulting in a significantly increased mortality rate in the inten-
sive therapy group. As a result, these findings raised the possi-
bility of a previously unrecognized risk associated with inten-
sive glucose lowering in high-risk patients who have type 2 di-
abetes.
  Primary outcome: a composite of non-fatal myocardial in-
farction, non-fatal stroke, or death from cardiovascular causes.
Action in Diabetes and Vascular Disease: Preterax and 
Diamicron Modified Release Controlled Evaluation 
(ADVANCE) study [6]
This study was carried out with the same goal as that of the 
ACCORD study. It was different from the ACCORD study in 
that the target HbA1c goal was set below 6.5% for the intensive 
therapy group, gliclazide (modified release) was chosen as the 
basic treatment, and additional medication was added depend-
ing on need. A total of 11,140 patients with type 2 diabetes and 
a mean age of 66 were included in the study. The median HbA1c 
concentration before the start of the study was 7.2%. The me-
dian follow-up period was five years. The median HbA1c con-
centration after five years was 6.5% in the intensive treatment 
group and 7.3% in the standard treatment group. The intensive 
treatment group showed a 10% reduction in the incidence of 
the primary outcome (18.1% vs. 20.0%; hazard ratio, 0.90; 95% 
CI, 0.82 to 0.98; P = 0.01). These results were primarily due to 
a reduction in the incidence of nephropathy. There were no 
statistical differences between the two groups in regard to ma-
jor macrovascular events, deaths from cardiovascular causes, 
or deaths from any other cause.
  Primary outcome: a composite of major macrovascular events 
(death from cardiovascular causes, non-fatal myocardial infarc-18
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tion, or non-fatal stroke) and major microvascular events (new 
or worsening nephropathy or retinopathy).
Veterans Affairs Diabetes Trial (VADT) [7]
This study enrolled 1,792 patients who had type 2 diabetes. 
They had an average age of 60.4 years, and 97% of the patients 
were male. The study population was randomly divided into 
intensive and standard treatment groups. The average HbA1c 
concentration at the start of the study was 9.4%. After an aver-
age follow-up period of 5.6 years, the HbA1c values dropped 
to an average of 6.0% in the intensive treatment group and to 
8.4% in the standard treatment group. There were no statisti-
cally significant differences between the two groups in the pri-
mary outcome measurements or death rates from all causes. 
In addition, there were no differences in microvascular com-
plications between the two groups.
  Primary outcome: The time from randomization to the first 
occurrence of a major cardiovascular event. A major cardio-
vascular event was defined as a myocardial infarction, stroke, 
death from cardiovascular causes, congestive heart failure, sur-
gery for vascular disease, inoperable coronary disease, or am-
putation due to ischemic gangrene.
Effect of intensive control of glucose on cardiovascular 
outcomes and death in patients with type 2 diabetes:  
a meta-analysis of randomized controlled trials [9]
According to the results mentioned above, the American 
Heart Association, the American College of Cardiology, and 
the American Diabetes Association set the preventive effects 
of glycemic control for cardiovascular diseases as a Class IIb 
recommendation. However, individual studies have shown 
that the control of risk factors associated with cardiovascular 
disease has improved. The results showed a reduced incidence 
of cardiovascular disease. The treatment period was too short 
and the differences in glycemic control were too small to ex-
pect sufficient beneficial effects. Ray et al. [9] assessed the effects 
of intensive glucose control using a meta-analysis. Five studies 
(UKPDS [1], PROactive [10], ADVANCE [6], VADT [7], AC-
CORD [5]) were chosen for inclusion in the review. After ana-
lyzing 33,040 patients, intensive glycemic control (0.9% drop 
in HbA1c levels for five years) was found to reduce the rate of 
non-fatal myocardial infarctions by 17% (odds ratio, 0.83; 95% 
CI, 0.75 to 0.93) and that of coronary heart disease by 15% (0.85; 
0.77 to 0.93). However, it did not decrease the death rates due 
to stroke or any other causes of mortality.
THE REASON FOR INCREASED MORTALITY 
IN THE GROUP WITH INTENSIVE GLUCOSE 
CONTROL IN THE ACCORD STUDY
The increased mortality observed in the ACCORD study was 
likely due to the frequency of significant hypoglycemic events, 
the significant increase in the use of insulin or thiazolidine-
diones and drug combinations, as well as weight gain. Howev-
er, these explanations require confirmation. Significant hypo-
glycemia may increase the risk of cardiovascular disease due 
to subclinical cardiovascular autonomic dysfunction in patients 
who are at high risk for cardiovascular disease. This could in-
crease the risk of sudden death. Because glucose was tightly 
controlled in the intensive treatment group, the complex com-
bination of stress, an unknown impact of the drugs used in com-
bination with insulin and their frequent modifications, and 
weight gain may have contributed to the outcome.
  The death rate did not increase in the ADVANCE study de-
spite a similar intensive glucose control. The average patient in 
the ADVANCE study had diabetes for eight years, two years less 
than the average patient in the ACCORD study. The median 
HbA1c level was 7.2% at the start of the study. This was lower 
than that of the ACCORD study (8.1%). The blood glucose was 
gradually lowered after the study began, and the weight gain 
was not significant. The incidence of severe hypoglycemia was 
less than 3% over five years. This was relatively low compared 
to that of the ACCORD (16%) and the VADT studies (21%). 
Therefore, it is possible that the increased mortality seen in the 
intensive treatment group of the ACCORD study could have 
been due to the treatment strategy used for lowering blood glu-
cose.
RECOMMENDATIONS FOR CLINICAL 
MANAGEMENT
It is beneficial for people who have diabetes (type 1 or type 2) 
to control their blood glucose so that it is as close to normal as 
possible. Large studies [5-8] have shown that intensive glycemic 
control does not prevent cardiovascular disease, the most sig-
nificant cause of death associated with type 2 diabetes. How-
ever, this does not reduce the significance of intensive glycemic 
control. In addition to treatments for other cardiovascular dis-
ease risk factors (including the use of anti-hypertensive medi-
cations and statins), the effects of intensive glycemic control 
were too small to show any clinical benefit with regard to car-19
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diovascular disease. There was no reduction in the frequency 
of myocardial infarctions in the intensive glycemic control 
group of the UKPDS study. However, an extension of the initial 
randomized groups in the UKPDS study showed a reduction 
in the frequency of myocardial infarctions and all-cause mor-
tality with intensive glucose control [11]. Therefore, the clini-
cal benefits of intensive glycemic control cannot be observed 
over a relatively short period of time.
  Improved outcomes require both drug treatment and life-
style modifications for most people who have type 2 diabetes. 
However, most people with type 2 diabetes depend on drug 
treatment because lifestyle changes are harder to implement. 
Blood glucose-lowering drugs have side effects in addition to 
their beneficial effects of reducing the blood glucose levels. The 
longer a person has diabetes, the greater is the likelihood that 
they will require an increased number of drugs and therefore 
have an increased risk of experiencing these side effects. Because 
of this, it is hard to reach a consensus on treatment. A compro-
mise on treatment methods must be reached based on the med-
ical and ethical situation of each individual patient. Complete 
knowledge of the patient’s condition is required in order to make 
the best judgment.
  Currently, the Korean Diabetes Association does not rec-
ommend changing the blood glucose treatment goal below an 
HbA1c of 6.5%. This is the target recommended by the exist-
ing guidelines [4] for the prevention of diabetic complications. 
However, considering the results of the studies discussed above 
and the goal of individualizing care for diabetic patients, the 
following recommendations are suggested.
1) For newly diagnosed people with type 2 diabetes, intensive 
glucose control is required during the early stage. Only pa-
tients who have cardiovascular disease or those who are at 
high risk for cardiovascular disease require individually es-
tablished goals for blood glucose values. Active manage-
ment of other cardiovascular risk factors (such as smoking, 
sedentary life style, poor eating habits, dyslipidemia, and 
hypertension) is also required.
2) Intensive glucose control is also required for people with 
type 2 diabetes who are already being treated. Only patients 
who have cardiovascular disease or those who are at high 
risk for cardiovascular disease require individually estab-
lished goals for blood glucose values. Blood glucose levels 
should be gradually decreased in order to prevent a large 
variability of blood glucose by diabetic drug treatments. 
Active management of other cardiovascular risk factors 
(such as smoking, sedentary life style, poor eating habits, 
dyslipidemia, and hypertension) is also required.
THE CONCLUSIONS FROM THESE RECENT 
STUDIES
Based on the results of recent studies which examined out-
come results by setting specific goals for low-density lipopro-
tein cholesterol (ENHANCE) [12], high-density lipoprotein 
cholesterol (ILLUMINATE) [13], blood pressure (ONTAR-
GET) [14], and HbA1c (ACCORD) [5] in order to prevent the 
occurrence of cardiovascular disease in high risk patients, in-
cluding people with type 2 diabetes, it became clear that it is 
not important only to reach specific goals for these cardiovas-
cular disease risk factors. However, different outcomes can be 
obtained depending on the method that is used to reach the 
target. The treatment guidelines have been developed based 
on the data that has been gathered to so far. Most analyses of 
these study results are based on determining whether or not 
the risk factor goals have been reached, without considering 
the quality of the treatments. It is necessary to evaluate the 
treatment method in terms of clinical benefits and risks in or-
der to determine the possible overall clinical outcomes, in-
cluding an improvement in the quality of life and prevention 
of complications.
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